Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ706MR)

This product GTTS-WQ706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ706MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7476MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ918MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ5277MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ5901MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ6181MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ6836MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ2675MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ6274MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW